Chimeric fusion proteins - Diphtheria toxin-based

A. E. Frankel, B. L. Powell, D. A. Vallera, Jr Neville D.M.

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

Most cancer patients receive chemotherapy drugs that target DNA or the cell division apparatus. Many of these patients develop multidrug-resistant tumor cells, thus, novel methods to overcome drug resistance are needed. One approach is to target tumor cell protein synthesis. Peptide toxins, which catalytically inactivate protein synthesis, have been re-engineered to selectively bind and intoxicate tumor cells. Diphtheria toxin (DT), a member of the class of peptide toxins, has been subjected to structural and genetic analysis and protein engineering for several decades. In this review, we will examine the structure, function, synthesis and pharmacology of anticancer DT conjugates.

Original languageEnglish (US)
Pages (from-to)1294-1301
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Volume2
Issue number9
StatePublished - Oct 1 2001

    Fingerprint

Keywords

  • Cell surface receptors
  • Diphtheria toxin
  • Fusion proteins
  • Immunotoxins
  • Receptor-mediated endocytosis
  • Toxin conjugates

ASJC Scopus subject areas

  • Pharmacology

Cite this

Frankel, A. E., Powell, B. L., Vallera, D. A., & Neville D.M., J. (2001). Chimeric fusion proteins - Diphtheria toxin-based. Current Opinion in Investigational Drugs, 2(9), 1294-1301.